Deplin (L-Methylfolate) for Heterozygous MTHFR Mutation
For heterozygous MTHFR mutations without documented hyperhomocysteinemia (homocysteine <15 μmol/L), L-methylfolate supplementation is not routinely indicated based on genotype alone, as the mutation by itself does not confer cardiovascular risk or require treatment. However, if elevated homocysteine levels are present (≥15 μmol/L), oral 5-MTHF (L-methylfolate) treatment should be considered 1.
What is Deplin?
Deplin is a prescription medical food containing L-methylfolate (also called 5-MTHF or 5-methyltetrahydrofolate), which is the active, methylated form of folate that the body can directly utilize. Unlike folic acid, L-methylfolate does not require conversion by the MTHFR enzyme to become biologically active 1.
How MTHFR Mutations Affect Folate Metabolism
The MTHFR enzyme converts dietary folate (and supplemental folic acid) into 5-methyltetrahydrofolate, the active form needed for:
- Homocysteine metabolism (converting homocysteine to methionine)
- DNA synthesis and methylation
- Neurotransmitter production (dopamine, serotonin, norepinephrine)
The C677T polymorphism is found in heterozygous form in 30-40% of the general population and homozygous form in 10-15% 2. The heterozygous state causes mild reduction in enzyme activity, while homozygous (T/T) genotype produces a thermolabile variant with more significantly reduced function.
Clinical Indications for L-Methylfolate
When Treatment IS Indicated:
Measure homocysteine levels first. Treatment decisions should be based on actual homocysteine elevation, not genotype alone 1, 2, 3.
- Moderate hyperhomocysteinemia (15-30 μmol/L) with MTHFR 677TT (homozygous) genotype: Oral 5-MTHF treatment should be considered since this agent bypasses the defective MTHFR enzyme 1
- Documented folate deficiency with MTHFR mutation
- Treatment-resistant depression in patients with MTHFR polymorphisms (emerging evidence) 4, 5
When Treatment is NOT Routinely Indicated:
- Heterozygous MTHFR mutation alone without elevated homocysteine 2
- Normal homocysteine levels (<10-15 μmol/L), regardless of genotype
- General population in folate-fortified areas (North America) already receiving adequate dietary folate 1
Important Clinical Caveats
The Genotype vs. Phenotype Distinction
Critical pitfall: The MTHFR C677T variant by itself is NOT associated with arterial thrombosis in the absence of hyperhomocysteinemia, and is NOT associated with venous thrombosis in any case 2. Homozygosity for the 677C→T variant increases risk for hyperhomocysteinemia, which in turn increases cardiovascular risk—but the variant alone without elevated homocysteine does not require treatment.
Plasma homocysteine measurement is more informative than molecular testing because homozygosity for the C677T mutation accounts for only about one-third of hyperhomocysteinemia cases 2.
Dosing Considerations
- Standard folic acid (400 μg/day, the RDA) achieves 25-30% reduction in homocysteine 1
- Higher doses of folic acid provide no additional vascular benefit in folate-replete populations 1
- For MTHFR 677TT genotype with elevated homocysteine: L-methylfolate bypasses the enzymatic defect and may be more effective than folic acid 1
- Typical L-methylfolate dosing: 5-15 mg daily (based on clinical studies) 6, 4
Heterozygous MTHFR: The Evidence Gap
For heterozygous carriers specifically: The evidence does not support routine supplementation. Heterozygotes have only mildly reduced enzyme activity and typically maintain normal homocysteine levels with adequate dietary folate intake 2. In folate-fortified populations (like the U.S.), heterozygous individuals generally do not develop hyperhomocysteinemia requiring treatment.
Mechanism of Benefit (When Indicated)
L-methylfolate works by:
- Bypassing the MTHFR enzyme defect entirely—it's already in the active form 1
- Lowering homocysteine through the remethylation pathway (converting homocysteine to methionine)
- Supporting neurotransmitter synthesis (particularly relevant in depression treatment) 6, 5
- Providing bioavailable folate without requiring enzymatic conversion
Clinical Algorithm
Step 1: Identify MTHFR genotype (if testing performed)
- Heterozygous (C/T): Mild reduction in enzyme activity
- Homozygous (T/T): Significant reduction in enzyme activity
Step 2: Measure fasting plasma homocysteine (this is the critical step)
- <10-15 μmol/L: Normal—no treatment needed regardless of genotype
- 15-30 μmol/L: Moderate elevation—consider treatment, especially if homozygous T/T
30 μmol/L: Significant elevation—requires treatment and investigation of cause
Step 3: If homocysteine is elevated:
- Check folate, vitamin B12, B6 levels
- Assess for other causes (renal function, medications, thyroid function)
- For MTHFR-related elevation: L-methylfolate 5-15 mg daily
- May combine with B12 (0.02-1 mg/day) for additional 7% homocysteine reduction 1
Step 4: Monitor response
- Recheck homocysteine after 4-8 weeks of treatment
- Target: Homocysteine <15 μmol/L (ideally <10 μmol/L)
Safety Profile
L-methylfolate has demonstrated an excellent safety profile in preclinical studies with no adverse effects at doses up to 1000 mg/kg/day in animal studies 7. It is generally well-tolerated with minimal side effects reported in clinical use.
Bottom Line for Heterozygous MTHFR
Being heterozygous for MTHFR C677T is extremely common (30-40% of the population) and does not automatically warrant treatment. The key is measuring actual homocysteine levels. If homocysteine is normal, no intervention is needed. If elevated, L-methylfolate provides a rational treatment option that bypasses the enzymatic defect, though even heterozygotes often respond adequately to standard folic acid supplementation when needed 1, 2, 1.